The live biotherapeutic SYNB1353 decreases plasma methionine via directed degradation in animal models and healthy volunteers
Cell Host & Microbe · 2024
DOI: 10.1016/j.chom.2024.01.005 ↗Kurz gefasst
Kommentar in der Zeitschrift Cell Host & Microbe, 2024. Verfasst von Mylène Perreault und 17 weiteren Autor:innen. Beteiligte Einrichtung: Synlogic, Inc., Cambridge, MA 02142, USA. Electronic address: mylene@synlogictx.com. Hauptthemen laut MEDLINE: Methionine, Homocystinuria. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Methionine is an essential proteinogenic amino acid, but its excess can lead to deleterious effects. Inborn errors of methionine metabolism resulting from loss of function in cystathionine β-synthase (CBS) cause classic homocystinuria (HCU), which is managed by a methionine-restricted diet. Synthetic biotics are gastrointestinal tract-targeted live biotherapeutics that can be engineered to replicate the benefits of dietary restriction. In this study, we assess whether SYNB1353, an E. coli Nissle 1917 derivative, impacts circulating methionine and homocysteine levels in animals and healthy volunteers. In both mice and nonhuman primates (NHPs), SYNB1353 blunts the appearance of plasma methionine and plasma homocysteine in response to an oral methionine load. A phase 1 clinical study conducted in healthy volunteers subjected to an oral methionine challenge demonstrates that SYNB1353 is well tolerated and blunts plasma methionine by 26%. Overall, SYNB1353 represents a promising approach for methionine reduction with potential utility for the treatment of HCU.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Synlogic, Inc., Cambridge, MA 02142, USA. Electronic address: mylene@synlogictx.com.
- Synlogic, Inc., Cambridge, MA 02142, USA.
- Ginkgo Bioworks, Boston, MA 02210, USA.
- Human Predictions LLC, Boston, MA 02115, USA.
Zitieren
APA
Perreault, M., Means, J., Gerson, E., James, M., Cotton, S., Bergeron, C. G., Simon, M., Carlin, D. A., Schmidt, N., Moore, T. C., Blasbalg, J., Sondheimer, N., Ndugga-Kabuye, K., Denney, W. S., Isabella, V. M., Lubkowicz, D., Brennan, A., & Hava, D. L. (2024). The live biotherapeutic SYNB1353 decreases plasma methionine via directed degradation in animal models and healthy volunteers. Cell Host & Microbe. https://doi.org/10.1016/j.chom.2024.01.005
Vancouver
Perreault M, Means J, Gerson E, James M, Cotton S, Bergeron CG, et al. The live biotherapeutic SYNB1353 decreases plasma methionine via directed degradation in animal models and healthy volunteers. Cell Host & Microbe. 2024. doi:10.1016/j.chom.2024.01.005
BibTeX
@article{Perreault2024,
author = {Perreault, Mylène and Means, Jillian and Gerson, Erik and James, Michael and Cotton, Sean and Bergeron, Christopher G and Simon, Mark and Carlin, Dylan Alexander and Schmidt, Nathan and Moore, Theodore C and Blasbalg, Julie and Sondheimer, Neal and Ndugga-Kabuye, Kenneth and Denney, William S and Isabella, Vincent M and Lubkowicz, David and Brennan, Aoife and Hava, David L},
title = {The live biotherapeutic SYNB1353 decreases plasma methionine via directed degradation in animal models and healthy volunteers},
journal = {Cell Host & Microbe},
year = {2024},
doi = {10.1016/j.chom.2024.01.005}
}
EUVIMED